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SC sister is 50 years old and does not have renal failure, ac-
cording to the patient. The AC and AS brothers are 41 to 52
years old and all are healthy without renal failure, according
to the patient.
DISCUSSION
Dr. Donald E. Wesson (Chief, Combined Program
in Nephrology and Renal Physiology; and Chairman, De-
partment of Internal Medicine, Texas Tech University
Health Sciences Center, Lubbock, Texas, USA): Patients
with sickle cell disease (SCD) are living longer [1], but
longevity of African-Americans with SCD remains con-
siderably shorter than that in blacks without SCD [2].
African-American men and women with SCD examinedCASE PRESENTATION
between 1978 and 1988 lived an average of 42 and 48A 35-year-old African-American man with sickle cell disease
years, respectively [2], compared to 65 and 74 years for(SCD) and end-stage renal disease (ESRD) began chronic hemo-
dialysis 8 years ago. He averages one to three pain crises per black men and women in the general US population
year and requires an average of two units of packed red blood during a similar time period [3]. Renal failure occurs in
cells per month to maintain a hemoglobin of 7 to 8 g/dL despite 4% to 18% of SCD patients [4, 5] but in only 1% of
receiving 200 U/kg of subcutaneous recombinant erythropoie- the US population [6]. The average age at onset of ESRD
tin per dialysis treatment and having no evidence of external
in SCD patients from 1992 to 1997 was 40 years com-blood loss. He had one episode of acute chest pain syndrome
pared to 64 years for patients without SCD (Abbott KC,that resolved with conservative management. His hemoglobin
Hyolito I, Agodoa LY, personal communication). Thus,electrophoresis reveals 4% to 6% hemoglobin F with 90%
SCD patients develop ESRD more frequently and at anhemoglobin S. He refused treatment with hydroxyurea because
of fear of side effects. At age 14, he had had microscopic hema- earlier age compared with the non-SCD US population.
turia and dipstick-positive proteinuria; his plasma creatinine Renal failure is an important determinant of early death
concentration of 0.7 mg/dL was normal for his age and body in SCD [2], so reducing its frequency might increase the
mass. At age 19, his plasma creatinine was 1.4 mg/dL, and it
longevity of these patients. Alternatively, improvementsprogressively increased thereafter until he began hemodialysis
in SCD management that increase longevity but do notat age 28. He has not had a renal biopsy.
reduce ESRD risk potentially increase ESRD preva-The patient had five brothers and three sisters. Two sisters
lence. As with other forms of ESRD, prevention is thehad SS hemoglobin genotype, one brother and one sister had
SC, two brothers had AC, and two brothers had AS. One of goal, but designing effective preventive strategies re-
his two SS sisters began hemodialysis last month at age 22, quires an improved understanding of the mediating fac-
and the other SS sister died at age 40 for reasons unknown to tors for initiation and progression of SCD-associated
the patient; she never required renal replacement therapy. His renal disease.SC brother died at age 60 while on hemodialysis. The remaining
In this review, I will explore factors that might initiate
SCD nephropathy and mediate its progression toward
ESRD. I will offer a hypothesis for initiation and progres-The Nephrology Forum is funded in part by grants from Amgen,
Incorporated; Merck & Co. Incorporated; Dialysis Clinic, Incorpo- sion of SCD-associated nephropathy that can, and hope-
rated; and Bristol-Myers Squibb, Inc. fully will, be tested. Because progression to ESRD in
SCD-associated renal failure has features common toKey words: papillary necrosis, focal segmental glomerulosclerosis,
membranoproliferative glomerulonephritis, end-stage renal disease. those of other causes of renal failure, a better under-
standing of renal disease progression in SCD-associated 2002 by the International Society of Nephrology
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renal failure might shed light on general mechanisms
that can be applied to other diseases. I will focus this dis-
cussion on homozygous (SS) SCD, not on the many
variants of this disease in which SS hemoglobin is com-
bined with other hemoglobin subtypes.
The major pathologies in SCD-associated renal failure
are papillary necrosis (PN), focal segmental glomerulo-
sclerosis (FSGS), and type 1 membranoproliferative glo-
merulonephritis (MPGN) [7]. A frequent complication
of SCD, PN was documented in 15% to 40% of patients
with SCD undergoing urography to work up symptoms
or urinary abnormalities, usually gross hematuria [8, 9].
Moreover, the frequency of PN among asymptomatic
SCD patients who systematically underwent urography
was 67% [10]. When PN is detected incidentally in SCD,
it seldom is associated with a measurable decline in GFR
[10], but we will look at how PN might set the stage for
subsequent renal failure in SCD. By contrast, renal biop-
sies in patients [5, 7, 11, 12] and autopsy studies [13]
suggest that FSGS is the most common cause of renal
failure in SCD. Moreover, clinicopathologic studies show
that the early lesion of most forms of SCD nephropathy
is glomerular enlargement with progressive development
of perihilar FSGS [7, 11]. These data support FSGS as
the major cause of SCD nephropathy (Fig. 1). Although
MPGN in SCD is morphologically similar to the classic
variety of this disease, few cases have the characteristic
immune deposits, particularly in the early stages [7, 11].
The etiology of MPGN in SCD is poorly understood,
but it is not the major cause of renal failure in SCD [7].
Consequently, the focus of this discussion will be on
FSGS as the major cause of SCD nephropathy and on
PN as the possible prodrome for the subsequent appear-
ance of FSGS.
SCD features that might contribute to FSGS
The mechanisms by which FSGS specifically and glo-
merulosclerosis in general develop are incompletely elu-
cidated, but many factors associated with FSGS are com-
mon in SCD. Three such characteristics might individually
Fig. 1. (A) Glomerulus from a patient with sickle cell disease (right)or in combination lead to FSGS and subsequent SCD- is much larger than one from an age-matched control (left) at the
associated renal failure. First, recent data suggest that same magnification. (B) Glomerular area indicated on the ordinate is
significantly larger in sickle cell patients than control. (From Ref. 13.)SCD is a state of oxidative stress [14]. In an animal model
of SCD, initiation, progression, and resolution of the
vaso-occlusive episodes that characterize SCD comprise
features of ischemia-reperfusion injury with the associ- commonly have supranormal levels of glomerular filtra-
ated chronic inflammatory response that includes activa- tion rate (GFR), that is, hyperfiltration [19, 20]. This
tion of white blood cells and a local increase in the oxi- phenomenon is associated with the subsequent develop-
dative state [14]. Activated monocytes/macrophages of ment of FSGS in human and animal models of this dis-
bone marrow origin play an important role in the patho- ease [21]. Indeed, the GFR of younger patients with SCD
genesis of glomerulosclerosis in experimental animals is higher than that of age, weight, and gender-matched
[15] and in humans [16]. In addition, oxidized plasma individuals without SCD [19] but the GFR subsequently
lipoproteins are implicated in the pathogenesis of glo- falls to the normal range for most middle-aged SCD
merulosclerosis both in experimental animals [17] and patients [20]. In addition, as I mentioned earlier, glomer-
ular enlargement, a pathologic correlate of hyperfiltra-humans [18]. Second, children and young adults with SCD
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tion, is a common early lesion of SCD nephropathy [11]. in SCD [26]. Vessel occlusion is also affected by local pro-
duction of cytokines that alter local factors in a wayThird, 20% to 30% of patients with SCD have protein-
uria [7], and chronic exposure of renal tubular epithelium that augments vascular occlusion [26]. Examples of these
local factors in animal models of SCD include recruit-to high levels of filtered plasma proteins might cause
tissue injury with a subsequent inflammatory response ment of pro-inflammatory cells [14] and local release of
vasoconstricting agents like endothelin [27], each phe-[22]. Remuzzi and Bertani suggest that filtered plasma
proteins taken up by tubular epithelium stimulate in- nomenon potentially impeding escape of sickled RBCs.
Individual variation in SS hemoglobin polymerization,flammatory genes and release inflammatory and vaso-
active substances into the renal interstitium that induce RBC vascular adhesion, and cytokine production might
determine the degree of PN in patients with SCD.scarring and sclerosis [22]. These three features of SCD
likely contribute synergistically to the high rate of renal Hemoglobin SS crystallizes to form the sickled RBCs
by a process with the characteristics of nucleation-initi-failure in these patients. Also, that only a minority of
SCD patients develop renal failure suggests that geneti- ated polymerization [28]. The most important step in
the cascade leading to SS hemoglobin polymerization iscally determined activity of non-SCD genes acts with
these three factors to determine the risk of renal failure formation of a critical nucleus of tetramers, after which
polymerization proceeds rapidly. The time required toin an individual with SCD.
form this critical nucleus, known as the “delay time,” is
Papillary necrosis ordinarily greater than the transit time through the mi-
crocirculation of most tissues, thereby sparing SCD pa-Papillary necrosis in SCD can present dramatically
with renal colic, gross hematuria, and acute renal failure tients from ongoing massive and constant RBC sickling.
The risk for SS hemoglobin polymerization is increasedwith or without urinary tract obstruction [7, 8, 23]. More
commonly, PN in SCD follows a more protracted course by low O2 tension, hypertonicity, and low pH [28], all
characteristics of the renal medulla [7]. Nevertheless,of months to years interrupted by recurring episodes of
gross hematuria and/or urinary tract infection [7, 23]. individual variability in the degree of PN in patients with
the same SCD genotype suggests that additional factorsPapillary necrosis in SCD is commonly asymptomatic,
and its frequency among asymptomatic SCD patients are important. For example, genetically controlled activ-
ity of RBC membrane cation transporters [26] deter-is probably high [10]. Patients with SCD who develop
symptomatic PN sometimes have blood clots and/or mines RBC volume and thereby intracellular hemoglo-
bin concentration [29], an important determinant of thesloughed papillary tissue in their urine, but this finding was
infrequent in one large series, and acute urinary tract sickling risk. Also, SCD patients with higher levels of fe-
tal hemoglobin or of hemoglobin A2 have a lower riskobstruction was even less frequent [23]. Altogether, PN
is commonly diagnosed as an incidental finding in the for SS hemoglobin polymerization [30]. The level of syn-
thesis of these hemoglobin subtypes is under individualurologic workup of patients with SCD and is seldom a
cause of renal failure at the time it occurs. Nevertheless, genetic control separate from that of SS hemoglobin [30,
31]. Individual variation in the expression of these andPN might set the stage for the subsequent development
of FSGS, as I will discuss later. probably other factors in SCD patients helps determine
the degree of SS hemoglobin polymerization and therebyLet’s turn our attention to the pathogenesis of PN in
SCD. Papillary necrosis in SCD is mediated by blood infarction of papillary tissue with subsequent PN.
In addition to hemoglobin S polymerization, the de-vessel occlusion that causes infarction and necrosis of
papillary tissue, the degree of which varies [7]. In most gree to which sickled RBCs adhere to vascular endothe-
lium is an important component of the cascade leading topatients with SCD, the infarcted areas are small, and
renal function, as measured clinically, usually is not af- blood vessel occlusion in SCD [26]. Sickled RBCs ad-
here to cultured non-human vascular endothelial cellsfected [23], at least not immediately. Less commonly,
SCD patients have more widespread necrosis of the pa- [32], to cultured human vascular endothelial cells [33],
and to vascular endothelium of in vivo animal modelspilla [24] due to more extensive infarction. Given that
these patients all have the same SS genotype, these data of SCD [34]. Patients with SCD have elevated plasma
levels of the endothelial adhesion proteins von Wille-suggest that individual variability in non-SCD genes
helps determine the degree of blood vessel occlusion brand factor (vWF), vascular endothelial adhesion mole-
cule-1 (VCAM-1), and intercellular adhesion molecule-1with infarction. Thus, while sickle hemoglobin is caused
by a single mutation, SCD could be a multi-gene disease (ICAM-1) [35, 36], and vWF and VCAM-1 mediate ad-
hesion of sickled RBCs to vascular endothelium [26].[25], and this concept helps account for the variable
severity of disease, including the degree of PN, among Patients with SCD also have plasma markers of vascular
endothelial injury [36], and endothelial injury itself in-SCD patients. I will return to this concept later.
Both SS hemoglobin polymerization and red blood cell creases vWF and VCAM-1 release from the vascular
endothelium [36, 37]. In addition, sickled RBCs induce(RBC) vascular adhesion mediate blood vessel occlusion
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expression of VCAM-1 and ICAM-1 in human vascular of PN [42]. The patient presented today had macropro-
teinuria many years before his plasma creatinine concen-endothelial cells in vitro [38]. Monoclonal antibodies
that block adhesion molecules inhibit adhesion of sickled tration was noted to exceed the normal range. The stud-
ies I have mentioned are consistent with a scenario inRBCs to vascular endothelium [39]. This finding further
demonstrates the importance of these molecules in medi- which hyperfiltration combined with increased glomeru-
lar filtration of plasma proteins contributes to FSGS andating adherence of sickled RBCs to the vascular endothe-
lium. Adhesion molecules also mediate polymorphonu- a progressive decline in GFR.
clear leukocyte attachment to vascular endothelium, and
Focal segmental glomerulosclerosisattachment of these larger and less deformable cells dra-
matically impedes RBC passage, increasing the risk for Focal segmental glomerulosclerosis, associated with
many pathologic processes including SCD, is the finalsickling and vascular occlusion [40]. Furthermore, imma-
ture, larger RBCs are more likely than mature ones to common pathway toward ESRD in many renal paren-
chymal diseases [41]. The lesion has been divided intoadhere to vascular endothelium [26]. There is individual
variability among SCD patients in their marrow response “classic” and “collapsing” varieties according to its patho-
logic appearance. The two varieties are thought to beto the increased RBC destruction that characterizes SCD
[31]; variability in the release of immature RBCs thus due to different mechanisms. Classic FSGS begins with
segmental “tuft adhesions” of the glomerular capillarymight contribute to the individual variability in the de-
gree of vaso-occlusive disease, including PN, among SCD to the surrounding parietal epithelium that progress to
segmental collapse of the glomerular capillary with even-patients. Additionally, the degree of expression of endo-
thelial cell integrins appears to be genetically deter- tual sclerosis that can subsequently involve the entire
glomerulus [48]. This is the most common variety ofmined, and adhesion of RBCs and WBCs to the vascular
endothelium is determined by the degree of expression FSGS and includes that described in SCD. By contrast,
the collapsing variety begins with global collapse of theof these substances [26].
Although PN in SCD is not commonly associated with capillary tuft and leads to global sclerosis [48]; it is best
exemplified by HIV nephropathy. Although the patho-reduced renal function, some associated features might
“set the stage” for the subsequent development of FSGS. genesis of FSGS is incompletely understood, the classic
variety of this disorder is characterized by: (1) glomerularSupporting this hypothesis is the fact that FSGS occurs
as a late consequence of many disease processes in hu- hypertrophy and/or hyperplasia; (2) glomerular capillary
hypertension with or without systemic hypertension; (3)mans that cause PN [41] and in the bromoethylamine
(BEA)-induced experimental model of PN [42]. Two podocyte damage; and (4) mesangial damage including
“insufficiency” and mesangiolysis [48]. Two other fea-characteristics of PN that might facilitate the subsequent
development of FSGS include glomerular hyperfiltration tures common to FSGS are variable degrees of mesangial
cell proliferation and/or matrix expansion along withand increased filtration of plasma proteins. Because jux-
tamedullary nephron damage is a common pathologic surrounding tubular atrophy and interstitial fibrosis [49].
Many SCD features directly or indirectly lead to all thesefeature in young SCD patients [43], and GFR in these
young patients generally is not reduced [19], surviving events and thereby increase the risk of FSGS for patients
with SCD.cortical nephrons in young patients with SCD and vari-
able degrees of PN might have a higher-than-normal Hyperfiltration with glomerular enlargement commonly
precedes the onset of FSGS both in animal and humanGFR. Indeed, patients with SCD have higher GFRs than
do age-matched controls [44]. In addition, single-neph- models of this disease [16, 41] including SCD [11, 50].
The cause of hyperfiltration in SCD is unknown butron GFR in the surviving cortical nephrons is higher
than control in the BEA model of PN, in which papillary might be mediated by an increased production of vasodi-
lating prostaglandins [51], prostacyclin [52], and/or nitricand deep nephron function is severely damaged [45].
Higher GFR in SCD is associated with increased glomer- oxide [53]. Some experimental PN models in which FSGS
subsequently develops are associated with increased glo-ular permselectivity and increased glomerular ultrafil-
tration coefficient [44]. On the other hand, urinary pro- merular capillary hydrostatic pressure [44]. This in-
creased hydrostatic pressure might lead to FSGS by di-tein excretion in SCD inversely correlates with GFR,
and proteinuria is associated with a reduced glomerular rectly or indirectly damaging podocytes, mesangial cells,
and endothelial cells of the glomerulus.ultrafiltration coefficient [46]. Furthermore, SCD pa-
tients with a more severe decrease in GFR have an in- Glomerular podocyte damage is an important event in
progression toward FSGS [48]. Unlike other glomerularcreased glomerular permeability to proteins of all sizes
as well as a markedly reduced glomerular ultrafiltration cells, podocytes appear to be unable to replicate, so when
they are damaged, they are irreversibly lost [48]. Severecoefficient [47]. Non-nephrotic proteinuria is common
in humans with PN of various causes [41] and is present podocyte damage leads to their detachment from the un-
derlying glomerular basement membrane. Because theirin experimental animals with the BEA-induced model
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interdigitating foot processes contribute importantly to
maintaining selectivity of the glomerular filtration bar-
rier, podocyte loss increases passage of plasma proteins
into the urinary space [54]. In addition, podocytes along
with mesangial cells and their matrix contribute to the
structural integrity of the glomerular capillary wall,
which sustains intra-luminal hydraulic pressure higher
than that in typical capillary systems [55]. Without the
external structural support provided by podocytes, the
glomerular capillary wall balloons outward, and the adja-
cent basement membrane loses its folding characteristics
[48]. The exposed, ballooning, and unfolded basement
membrane attaches to the parietal epithelium of Bow-
man’s capsule to form a tuft adhesion [48].
The segmental glomerular sclerosis that characterizes
FSGS begins with formation of the tuft adhesion, after
which the adjacent glomerular capillary wall hyalinizes;
this process leads to a progressive decrease in its lumen
Fig. 2. Compared to normal, the transgenic mouse model of sickle celldiameter with eventual obliteration [48]. The basement
disease produces higher levels of ethane, a measure of the productionmembrane surrounding the glomerular capillary and the of reactive oxygen species. This increase is most evident after the ani-
attached parietal epithelium eventually rupture. This tear mals are reoxygenated () following hypoxia; ( ) the baseline period.
(From Ref. 67.)permits extravasation of capillary luminal contents into
a space created between the external side of the parietal
epithelium and the basement membrane surrounding
Bowman’s capsule, as well as into the renal interstitium
that lead to FSGS are known, less clear are the events
[48]. Experimental models of FSGS show that activated
that initiate this cascade. Recent studies support injury toleukocytes including monocytes/macrophages enter this
the glomerular capillary endothelial cell as a critical firstspace [56], where they might induce sclerosis [57] and
step on the road to FSGS [59, 60]. Patients with SCD suf-thereby promote the glomerulosclerosis that character-
fer varying degrees of ongoing vascular endothelial in-izes FSGS. This space eventually fills with matrix ma-
jury. They have elevated plasma levels of markers thatterial contributed by mesangial cells and possibly by re-
reflect vascular endothelial injury [36] and elevated levelsmaining podocytes [48]. The sclerotic periglomerular
of denuded and circulating vascular endothelial cells dur-space is initially segmental but spreads circumferentially
ing crises [61] and even when asymptomatic [36]. Patientsto involve the entire glomerulus and increasingly com-
with SCD also have histologic damage to their vascularpresses the capillary tuft until the glomerulus becomes
endothelium [62]. Injury to the glomerular endotheliumnon-functional or nearly so. Mesangial damage with or
might be caused by high shear stress associated withwithout mesangial cell proliferation commonly accompa-
hyperfiltration [21]. It is important to note that animalnies FSGS [16, 49].
models of SCD have increased production of reactiveIn addition to the glomerular changes, interstitial in-
oxygen species (ROS) (Fig. 2) that cause vascular endo-flammation with sclerosis is a consistent feature of FSGS
thelial damage [14]. Following vaso-occlusive injury, this[48] and might be mediated by at least three mechanisms.
same model (Fig. 3) has increased emigration of acti-First, the damaged glomerulus permits capillary contents
vated leukocytes that produce ROS when they bind toto extravasate into the renal interstitium as described ear-
vascular endothelial cells expressing cell adhesion mole-lier, evoking an inflammatory reaction [48]. Second, cyto-
cules induced by exposure to sickle RBCs in vitro [38]kines released by invading activated leukocytes facilitate
and in vivo [14]. These recruited leukocytes produceprogression of interstitial inflammation to sclerosis and
ROS that directly damage vascular endothelium [14].fibrosis [58]. Third, severely damaged glomeruli with pa-
Sickle RBCs also produce ROS that damage vasculartent capillary loops have dramatically increased filtration
endothelium [63, 64]. These SS RBCs adhere to vascularof plasma proteins [55] that might evoke an inflammatory
endothelium [34] and do so more readily than do RBCsresponse from renal tubular epithelial cells [22]. The inter-
with normal hemoglobin [33]. Hemoglobin SS losesstitial inflammatory response caused by these factors in-
heme faster than normal hemoglobin due to acceleratedduces adjacent interstitial cells to proliferate and form
auto-oxidation [63]. Accelerated auto-oxidation of SSa continuous layer of thin sheet-like fibroblasts that sepa-
hemoglobin leads to increased production of ROS [64]rate the sclerotic glomerulus from the interstitium [48].
Although many components of the cascade of events and to increased deposition of iron that catalyzes ROS
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Table 1. Factors that likely cause FSGS in SCD
Increased production of reactive oxygen species due to
Hypoxia/reoxygenation
Recruitment of activated leukocytes
Auto-oxidation of sickle hemoglobin
Hyperfiltration of cortical nephrons due to
Papillary necrosis with medullary nephron damage
Cytokines from damaged vascular endothelium and activated leuko-
cytes
Chronic exposure of renal tubular epithelium to high levels of
filtered plasma proteins due to
Cortical nephron hyperfiltration
Podocyte damage
Glomerular tuft adhesions with glomerulosclerosisFig. 3. Emigration of leukocytes is greater following hypoxia/reoxy-
genation in the transgenic mouse model of sickle cell disease ( ) than Abbreviations are: FSGS, focal segmental glomerulosclerosis; SCD, sickle cell
in controls (). (From Ref. 14.) disease.
key factor in both the initiation and progression of SCDproduction in the membrane of SS RBCs [65]. The oxida-
nephropathy due to FSGS. This injury causes adhesiontive damage to vascular endothelium induced by SS RBCs
of sickled RBCs to vascular endothelium and increasesalso induces expression of cell surface adhesion mole-
vaso-occlusive disease. The renal medullary environmentcules, diapedesis of monocytes, and adherence of addi-
(hypoxic, hypertonic, and acidic) favors polymerizationtional SS RBCs to the vascular endothelium [66]. All these
of SS hemoglobin and greater microvascular occlusionevents occur in the transgenic SCD model [14, 67] and
in the papilla compared to other tissues, causing PN andall are ameliorated by inhibitors of ROS production [67].
medullary nephron damage. The resulting hyperfiltrationInvestigators have suggested analogies between glo-
of cortical nephrons, as well as ROS, injure glomerularmerulosclerosis and atherosclerosis [68], the latter being
cells and initiate the sclerotic process, the progress ofanother pathogenetic process in which vascular endothe-
which is promoted by cytokines from activated WBCslial injury is an important initial step [69] and for which
and possibly from injured vascular endothelium. Increasedoxidative stress augments progression [70]. Activated
filtration of plasma proteins due to glomerular damagemacrophages with foam cell formation contribute to pro-
induces interstitial inflammation that is facilitated bygression of glomerulosclerosis and atherosclerosis [68].
these same cytokines. Glomerulosclerosis combined withOxidized low-density lipoproteins found in atheroscle-
interstitial inflammation complete the picture of FSGS.rotic plaques [70] and in sclerotic segments of human
Renal failure is hypothesized to occur in only a minority
glomeruli with FSGS [18] stimulate production of extra-
of SCD patients because of genetically determined non-
cellular matrix by vascular smooth muscle cells in athero- SCD genes that mediate the degree of vaso-occlusive
sclerotic plaques [70] and similarly stimulate matrix pro- disease, which in turn helps determine the level of ROS.
duction by glomerular mesangial cells [71]. Oxidative Examples of these genetically determined factors include
stress injures glomerular mesangial cells [72] and podo- (1) the fetal hemoglobin level; (2) marrow production
cytes [48] and leads to sclerotic responses in both cell of immature RBCs that are more adherent to vascular
types [48, 72] as well as injures vascular endothelium, as endothelium; (3) adhesion molecule expression in response
I discussed earlier. Evidence supports the importance of to vascular endothelial injury; and (4) activity of RBC
oxidative stress to renal injury in a transgenic mouse cation transporters, which helps determine cell SS hemo-
model of SCD; inhibition of nitric oxide (NO) synthesis globin concentration. One of the two SS siblings of to-
and NO-mediated oxidant stress ameliorated renal cellu- day’s patient developed ESRD at age 22; the other died
lar injury [73]. These data suggest that preventive strate- at age 40 of unknown causes but without ESRD. Although
gies for atherosclerosis are effective in preventing initia- anecdotal, these data support the contribution of non-
tion and progression of FSGS in patients with SCD. SCD genes to the development of SCD nephropathy.
What causes FSGS in SCD? Hypothesized mecha-
Preventing SCD nephropathynisms for SCD nephropathy must include factors that
(1) initiate the cascade toward FSGS and facilitate its Investigations that have affirmed at least some ele-
progression to ESRD, and (2) explain why only a minor- ments of the hypothesis offered to account for the mech-
ity of SCD patients develop renal failure. Table 1 outlines anisms mediating SCD nephropathy have suggested po-
possible factors that contribute to FSGS in SCD. Chronic tential preventive strategies. Interventions that might
ameliorate hyperfiltration in SCD and thereby reducevascular endothelial injury induced by ROS might be a
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the risk of nephropathy include inhibitors of prostaglan- tubular acidosis similar to that seen in urinary tract ob-
struction [80]. These data suggest that hemoglobin Sdin and/or prostacyclin synthesis and inhibition of NO
synthase. The latter intervention ameliorated renal cellu- itself might be toxic to renal tubular function. Given that
the work to which I am alluding is more than 20 yearslar injury in an experimental model of SCD [73]. On the
other hand, prostaglandin inhibitors should be used with old, is there anything new about the role of hemoglobin
S in impairing renal function?caution in patients with SCD given their nephrotoxic
potential and demonstrated antinatriuretic effect of these Dr. Wesson: Hemoglobin S is a powerful oxidant and
contributes to oxidative stress in SCD [63, 64]. Extracel-agents in SCD [51]. In the renal ablation animal model
of FSGS characterized by glomerular hyperfiltration and lular hemoglobin S might exacerbate the interstitial dam-
age in SCD that can lead to tubular injury. As I men-hypertension, angiotensin converting enzyme (ACE) in-
hibitors decreased glomerular hyperfiltration and hyper- tioned, one can also make a case for proteinuria-induced
renal tubule injury.tension and reduced the risk for subsequent development
of FSGS [74]. Given the ability of ACE inhibitors to Dr. Barry Sobel (Texas Tech University Health Sci-
ences Center, Odessa, Texas): If proteinuria due to in-retard progression of renal diseases mediated by glomer-
ulosclerosis [75], investigators are currently testing the creased capillary pressure is the initiating factor in FSGS,
why do patients with analgesic nephropathy develop end-efficacy of these drugs to reduce the likelihood of renal
failure in patients with SCD [7]. Interventions that re- stage renal disease without developing severe proteinuria?
Dr. Wesson: First, let me say that I believe that papil-duce oxidant stress mediated by ROS also might reduce
the risk for nephropathy in SCD. Anti-oxidant therapy lary necrosis is an initiator and not the initiator of FSGS.
Let me follow by stating my bias that proteinuria is im-reduces cardiovascular end points in patients with ESRD
[76]. Given the similarities between FSGS and athero- portant, if not critical, in the development of FSGS in
sickle cell nephropathy. Second, patients with analgesicsclerosis that I described earlier, anti-oxidant therapy
might retard FSGS progression [69]. Finally, decreasing nephropathy typically have low-grade proteinuria, less
than 2 g/day, even in early stages of this process [39]. Uri-the traffic of plasma proteins across the glomerular base-
nary protein excretion reflects that amount which es-ment membrane in patients with SCD might reduce the
capes tubular reabsorption so that the renal tubules haverisk of nephropathy. It is encouraging that short-term
been exposed to levels that are much higher than thoseACE inhibition therapy reduces urinary albumin excre-
in the urine.tion in SCD patients [7, 77]. Longer-term studies cur-
Dr. Sharma Prabhakar (Texas Tech University Healthrently underway should determine whether this ACE
Sciences Center, Lubbock): Dr. Wesson, you mentionedinhibitor-induced reduction in urinary albumin excretion
that hyperfiltration is an important factor in the develop-translates into a reduced risk of renal failure.
ment and progression of sickle cell nephropathy. You also
alluded to the role of different factors including nitric
QUESTIONS AND ANSWERS oxide in explaining the hyperfiltration. Norman Bank’s
Dr. John T. Harrington (Dean, Tufts University group has shown activation of inducible nitric oxide syn-
School of Medicine, Boston, Massachusetts): Can one thase (iNOS) in transgenic models [53], so increased nitric
get FSGS in sickle cell disease if one has no papillary oxide production might explain the hyperfiltration. On
necrosis? the other hand, the same group subsequently showed that
Dr. Wesson: Autopsy studies show that every patient the activation of iNOS in the same model under hypoxic
with FSGS has at least some degree of papillary necrosis, circumstances leads to formation of peroxynitrate and
and in most cases it is severe. There is a very good con- superoxide, which, in turn, could cause apoptosis and the
nection between FSGS and papillary necrosis in sickle structural damage that characterizes sickle cell nephrop-
cell disease. athy [73]. Traditionally, iNOS-induced formation of per-
Dr. Neil Kurtzman (Texas Tech University Health oxynitrate and superoxide leads to decreased nitric oxide
Sciences Center, Lubbock, Texas): Don, you have con- levels. In addition, several investigators have shown that
vinced me about the glomerular disease, but I would like the acidosis that accompanies hypoxia also inhibits iNOS
to focus on some of the tubular abnormalities associated [81]; thus, the net effect of hypoxia on iNOS is unclear.
with SS hemoglobin. As you know, since you were there Consequently, are there mediators of hyperfiltration in
when it happened, we showed that the BEA model of SCD that are more important than nitric oxide? In partic-
papillary necrosis does not have hyperkalemic renal tu- ular, what is the role of the renin-angiotensin system in
bular acidosis [78]. De Fronzo showed that patients with sickle cell nephropathy?
hemoglobin S and normal renal function have a defect Dr. Wesson: As I alluded to, at least two other systems
in potassium excretion [79]. We subsequently showed contribute to hyperfiltration in sickle cell disease. One
that patients with abnormal renal function and a variety is the prostaglandin system. Allon et al showed that pros-
taglandin inhibitors decrease hyperfiltration in SS pa-of hemoglobin S pathologies have hyperkalemic distal
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tients and suggested a role for prostaglandins [51]. Addi- vitamin E reduces oxidant stress in SCD. Therefore, a
reasonable and relatively benign intervention for thetionally, that prostacyclin levels are increased in SCD
[52] suggests a role for this vasodilator with NO-medi- patient described would be ACE inhibitors.
Dr. Erdal Diri (Texas Tech University Health Sci-ated actions. The only study of which I am aware that
examines the GFR response of SCD patients given an- ences Center, Lubbock): You addressed the potential
role of VCAM-1 overexpression in the pathogenesis ofgiotensin-converting-enzyme inhibitors showed no GFR
change in response to this intervention [5]. These data SCD-related renal disease. What is the role of immuno-
suppressant therapy in SCD, especially that targetingsuggest that the renin-angiotensin system does not play
a major role in the hyperfiltration of SCD. these molecules?
Dr. Wesson: Reducing the response of the vascularDr. Melvin Laski (Texas Tech University Health Sci-
ences Center, Lubbock): I’d first like to comment relative endothelium to produce adhesion molecules with immu-
nosuppression therapy sounds like a good idea, but Ito the prior question about analgesic nephropathy. Anal-
gesic nephropathy occurs in later adulthood rather than am aware of no data regarding this intervention. In the
absence of such data I am hesitant to recommend anin childhood. Consequently, the difference between de-
velopment of FSGS in SCD and analgesic nephropathy intervention that is less benign than ACE inhibitors and
vitamin E.might be similar to the difference between being born
with one kidney and developing FSGS compared to los- Dr. Harrington: One of the things you commented
on in the case presentation was this patient’s need foring a kidney in adulthood and not developing FSGS.
The difference might be a matter of the age at which erythropoietin and frequent blood transfusions. Do we
know whether the site of erythropoietin productionthe renal mass was lost. My question goes to the clinical
correlates in nephropathy and SCD. Is there any rela- within the kidney is particularly damaged in patients
with sickle cell nephropathy?tionship between the clinical course of SCD and the risk
for developing nephropathy? Specifically, is there any Dr. Wesson: The only study of which I am aware that
tangentially addressed this issue showed that erythropoi-correlation with hemolytic crisis and exposure to acellu-
lar hemoglobin? etin production decreased in SS patients who developed
renal failure [82].Dr. Wesson: The only study of which I am aware that
addresses the relationship of the number of pain crises Dr. Harrington: I believe that there is an increased
incidence of uroepithelial carcinoma in patients withand the risk for subsequent sickle cell nephropathy is by
Powars et al [4]. In this study, patients with an increased sickle cell disease. Does that happen in patients with
other types of papillary necrosis?number of pain crises did not have an increased risk of
renal failure. Dr. Wesson: There is an increased incidence of uro-
epithelial cancer in patients with papillary necrosis, par-Dr. Everardo Cobos (Texas Tech University Health
Sciences Center, Lubbock): Is there any evidence that ticularly that due to analgesic nephropathy [83].
Dr. Harmohan Singh (Texas Tech University Healthhydroxyurea can ameliorate or prevent the progression
of the renal failure? Sciences Center, Lubbock): Dr. Wesson, you stated that
FSGS is the predominant lesion mediating sickle cellDr. Wesson: The answer is not known. The suspicion
is that it can, but no one has published a large enough nephropathy, but that a small minority of SS patients
has membranoproliferative GN. In sickle cell nephropa-series of patients followed long enough to be able to
answer the question. If vaso-occlusive disease is impor- thy, does membranoproliferative GN progress faster to
ESRD than FSGS does?tant in the development of SS nephropathy, then the
increased hemoglobin F induced by hydroxyurea should Dr. Wesson: There are no good prospective data to
answer this question. The data that exist suggest thatreduce the risk for SS nephropathy. This suggests that
the drug would be most useful in preventing SS nephrop- FSGS progresses faster to ESRD than does MPGN in
sickle cell nephropathy.athy if given in early childhood of SS patients.
Dr. Juan Sarria (Texas Tech University Health Sci- Dr. Prabhakar: You cited studies showing that ACE
inhibitors reduce proteinuria in SS patients and sug-ences Center, Lubbock): What should the primary care
physician do with the SCD patient who develops hematu- gested that these drugs might slow disease progression.
Are there any ongoing long-term studies with ACE in-ria or proteinuria but is normotensive?
Dr. Wesson: That is a question for which we have hibitors in sickle cell nephropathy? Second, has anyone
looked at microalbuminuria as a predictor of progressiveinsufficient data to adequately answer. Given that ACE
inhibitors reduce proteinuria in SCD [74], I suggest giv- renal disease in SCD?
Dr. Wesson: Yes, Dr. Falk’s group in North Carolinaing such a patient ACE inhibitors. Other data suggest that
oxidant stress is an important contributor, and some would is investigating the effect of ACE inhibitors on the pro-
gression of SS nephropathy [7]. Powars showed that dip-suggest that anti-oxidants such as vitamin E should be
given. Nevertheless, I am unaware of data showing that stick-positive proteinuria was predictive of nephropathy
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10. McCall IW, Moule N, Desal P: Urologic findings in homozygous[4], but I am not aware of studies that have examined
sickle cell disease. Radiology 126:99–104, 1978
the power of microalbuminuria to predict subsequent 11. Tejani A, Phadke K, Adamson O, et al: Renal lesions in sickle
cell nephropathy in children. Nephron 39:352–355, 1985sickle cell nephropathy.
12. Bhathena DB, Sondheimer JH: The glomerulopathy of homozy-Dr. Laski: This is a question about current SCD man-
gous sickle hemoglobin (SS) disease: Morphology and pathogene-
agement. I am well aware of this patient’s course and sis. J Am Soc Nephrol 1:1241–1252, 1991
13. Morgan AG, Shah DJ, Williams W: Renal pathology in adultsthe frequent need for transfusion. One of the conse-
over age 40 with sickle cell disease. West Indian Med J 36:241–250,quences of that over many years is iron overload that is
1987
particularly difficult to manage. What are we to do when 14. Kaul DK, Hebbel RP: Hypoxia/reoxygenation causes inflamma-
tory response in transgenic sickle cell mice but not in control mice.blood transfusions that maintain adequate blood counts
J Clin Invest 106:411–420, 2000also yield hemochromatosis?
15. Shiozawa S: Participation of macrophages in glomerular sclerosis
Dr. Wesson: The case presented is my personal pa- through the expression and activation of matrix metalloprotei-
nases. Pathol Int 50:441–457, 2000tient and I am currently facing that dilemma. We have
16. Noel LH: Morphological features of primary focal and segmen-unsuccessfully tried to convince him to take hydroxy-
tal glomerulosclerosis. Nephrol Dial Transplant 14(Suppl 3):53–
urea. This can increase hemoglobin F and thereby reduce 57, 1999
17. Magil AB, Frohlich JJ, Innis SM, Steinbrecher UP: Oxidizedthe vaso-occlusive disease that might be contributing to
low-density lipoprotein in experimental glomerulosclerosis. Kidneyhemolysis and his ongoing need for blood transfusions.
Int 43:1243–1250, 1993
I am not aware of any other reasonable options. 18. Lee HS, Kim YS: Identification of oxidized low-density lipoprotein
in human renal biopsies. Kidney Int 54:848–856, 1998Dr. Harrington: Are there are new ways of raising
19. Hatch FE Jr: Renal circulatory studies in young adults with sicklethe hemoglobin F level besides hydroxyurea?
cell anemia. J Lab Clin Med 76:632–640, 1970
Dr. Wesson: This nephrologist is not aware of any 20. Morgan AG, Serjeant GR: Renal function in patients over 40
with homozygous sickle-cell disease. Br Med J: 1181–1183, 1981ways to do that. However, more exciting are potential
21. Wesson LG: Physical factors and glomerulosclerosis. Nephrongene therapy approaches. Pawliuk et al just reported in
78:125–130, 1998
Science that an HIV vector, re-engineered to deliver the 22. Remuzzi G, Bertani T: Pathophysiology of progressive nephropa-
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